Brokerages Set HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Price Target at $20.88

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) has received an average recommendation of “Hold” from the five analysts that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $20.8750.

HCM has been the subject of several recent research reports. Wall Street Zen raised HUTCHMED from a “hold” rating to a “buy” rating in a research report on Sunday, November 16th. Weiss Ratings reissued a “hold (c)” rating on shares of HUTCHMED in a report on Wednesday, October 8th. Finally, Morgan Stanley downgraded shares of HUTCHMED from an “equal weight” rating to an “underweight” rating and lowered their target price for the stock from $18.00 to $13.75 in a report on Monday, September 22nd.

HUTCHMED Trading Up 0.1%

Shares of NASDAQ HCM opened at $15.31 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.51 and a current ratio of 4.65. The business has a 50-day moving average of $14.14 and a 200-day moving average of $15.42. HUTCHMED has a fifty-two week low of $11.51 and a fifty-two week high of $19.50.

Institutional Trading of HUTCHMED

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Personalized Indexing Management LLC grew its stake in shares of HUTCHMED by 23.2% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,490 shares of the company’s stock valued at $233,000 after acquiring an additional 2,916 shares in the last quarter. Ameriprise Financial Inc. boosted its holdings in HUTCHMED by 4.7% in the 2nd quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock valued at $234,000 after purchasing an additional 698 shares during the period. Bank of America Corp DE grew its position in shares of HUTCHMED by 17.3% during the 2nd quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock worth $310,000 after purchasing an additional 3,035 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of HUTCHMED by 34.2% during the third quarter. Dimensional Fund Advisors LP now owns 21,721 shares of the company’s stock worth $342,000 after purchasing an additional 5,538 shares during the period. Finally, BNP Paribas Financial Markets raised its position in shares of HUTCHMED by 19.7% in the second quarter. BNP Paribas Financial Markets now owns 25,046 shares of the company’s stock valued at $377,000 after buying an additional 4,116 shares in the last quarter. Institutional investors own 8.82% of the company’s stock.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.